Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma

Area of Science:

• Neuro-oncology
• Cancer Genomics
• Molecular Pathology

Background:

• Diffuse intrinsic pontine gliomas (DIPG) are aggressive pediatric brain tumors with currently incurable prognoses.
• The development of targeted therapies for DIPG necessitates the identification of actionable genetic alterations.
• Advanced genomic profiling technologies are crucial for discovering drugable mutations in rare cancers.

Purpose of the Study:

• To investigate the landscape of oncogenic mutations in newly diagnosed DIPG using a comprehensive gene panel.
• To identify potential therapeutic targets for DIPG based on detected genetic alterations.
• To assess the utility of advanced mutation detection technology in DIPG research.

Main Methods:

• Stereotactic biopsies were performed on twenty patients with newly diagnosed classic DIPG.
• OncoMap, a mass spectrometry-based method, was employed to analyze 983 mutations across 115 oncogenes and tumor-suppressor genes.
• Genomic data was analyzed to identify the frequency and spectrum of mutations present.

Main Results:

• Oncogenic mutations were identified in TP53 (40% of patients), PI3KCA (15%), and ATM/MPL (5%).
• Mutations in TP53 and PI3KCA represent significant findings in this DIPG cohort.
• No mutations were detected in numerous other genes frequently altered in malignant gliomas, highlighting DIPG-specific profiles.

Conclusions:

• The PI3K pathway is a relevant target for therapeutic intervention in DIPG at initial diagnosis.
• Identification of specific mutations like those in PI3KCA provides a rationale for targeted drug development in DIPG.
• This study underscores the importance of comprehensive genomic profiling for advancing DIPG treatment strategies.